These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Taking AIM at serious illness: implementing an access to investigational medicines expanded access program. Joly MM; Edwards TL; Jerome RN; Mainor A; Bernard GR; Pulley JM Front Med (Lausanne); 2023; 10():1287449. PubMed ID: 37877021 [TBL] [Abstract][Full Text] [Related]
5. Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic. Gravelin M; Wright J; Holbein MEB; Berro M; Brown JS; Mashour GA; Weatherwax KJ J Clin Transl Sci; 2021 Feb; 5(1):e94. PubMed ID: 34192051 [TBL] [Abstract][Full Text] [Related]
6. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation? Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691 [TBL] [Abstract][Full Text] [Related]
7. Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience. Berro M; Burnett BK; Fromell GJ; Hartman KA; Rubinstein EP; Schuff KG; Speicher LA; Acad Med; 2011 Feb; 86(2):217-23. PubMed ID: 21169787 [TBL] [Abstract][Full Text] [Related]
8. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center. Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568 [TBL] [Abstract][Full Text] [Related]
9. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs. Puthumana J; Miller JE; Kim J; Ross JS JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072 [TBL] [Abstract][Full Text] [Related]
10. Adapting an Expanded Access program to enable investigational treatments for COVID-19. Samuels E; Champagne E; Gravelin M; Racklyeft J; Weatherwax K J Clin Transl Sci; 2022; 6(1):e77. PubMed ID: 35836783 [TBL] [Abstract][Full Text] [Related]
11. Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies. Van Norman GA JACC Basic Transl Sci; 2018 Jun; 3(3):403-414. PubMed ID: 30062226 [TBL] [Abstract][Full Text] [Related]
12. A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to Try. Chapman CR; Belli HM; Leach D; Shah LD; Bateman-House A Med Access Point Care; 2021; 5():23992026211005991. PubMed ID: 36204503 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of initial progress to implement Common Metrics across the NIH Clinical and Translational Science Awards (CTSA) Consortium. Welch LC; Tomoaia-Cotisel A; Noubary F; Chang H; Mendel P; Parajulee A; Fenwood-Hughes M; Etchegaray JM; Qureshi N; Chandler R; Selker HP J Clin Transl Sci; 2020 Jul; 5(1):e25. PubMed ID: 33948248 [TBL] [Abstract][Full Text] [Related]
14. Overview of FDA's Expanded Access Program for Investigational Drugs. Jarow JP; Lurie P; Ikenberry SC; Lemery S Ther Innov Regul Sci; 2017 Mar; 51(2):177-179. PubMed ID: 28553565 [TBL] [Abstract][Full Text] [Related]
15. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs. Chapman CR; Eckman J; Bateman-House AS Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412 [TBL] [Abstract][Full Text] [Related]
16. Implementing Common Metrics across the NIH Clinical and Translational Science Awards (CTSA) consortium. Daudelin DH; Peterson LE; Welch LC; Chandler R; Pandey M; Noubary F; Lee PL; Selker HP J Clin Transl Sci; 2020 Feb; 4(1):16-21. PubMed ID: 32257406 [TBL] [Abstract][Full Text] [Related]
17. Expanded Access and Right To Try Requests: The Community Oncologist's Experience. Zettler ME; Jeune-Smith Y; Feinberg BA; Phillips EG; Gajra A JCO Oncol Pract; 2021 Nov; 17(11):e1719-e1727. PubMed ID: 33886355 [TBL] [Abstract][Full Text] [Related]
18. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. Bunnik EM; Aarts N BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313 [TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of the impact of standard agreement templates on multisite clinical trial start up time. Lawrence CE; Bruce VNM; Salberg LD; Edwards T; Morales C; Palm M; Bernard GR J Clin Transl Sci; 2023; 7(1):e204. PubMed ID: 37830004 [TBL] [Abstract][Full Text] [Related]
20. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try". Van Norman GA JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]